News

Actavis to acquire Durata Therapeutics for $675 million

Actavis to acquire Durata Therapeutics for $675 million

06-10-2014

In a move that takes it further out of its main generics business, Ireland-headquartered Actavis has…

ActavisAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsIrelandMergers & AcquisitionsPharmaceutical

Durata out-licenses dalbavancin to Angelini for certain territories

Durata out-licenses dalbavancin to Angelini for certain territories

30-07-2014

USA-based Durata Therapeutics says its Dutch subsidiary entered into a license and supply agreement with…

AngeliniAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsEuropeLicensingPharmaceutical

FDA approves Durata’s Dalvance to treat skin infections

26-05-2014

The US Food and Drug Administration last Friday approved Durata Therapeutics’ Dalvance (dalbavancin),…

Antibiotics and Infectious diseasesDalvanceDurata TherapeuticsPharmaceuticalRegulationUSA

Promising future for Cubist's Sivextro in anti-MRSA sector

04-04-2014

Following its launch, Cubist Pharmaceutical’s second generation oxazolidinone Sivextro Sivextro will…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDalvanceDurata TherapeuticsMarkets & MarketingoritavancinPharmaceuticalSivextroThe Medicines Company

FDA advisory unanimously recommends Durata’s Dalvance

FDA advisory unanimously recommends Durata’s Dalvance

01-04-2014

The US Food and Drug Anti-Infective Drugs Advisory Committee voted 12 to 0 that Durata Therapeutics’…

Antibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsNorth AmericaPharmaceuticalRegulationUSA

FDA accepts priority review of Durata NDA for Dalvance

FDA accepts priority review of Durata NDA for Dalvance

27-11-2013

Shares of Durata Therapeutics leapt 13.4%, following the news that the New Drug Application for its investigational…

Antibiotics and Infectious diseasesCubicinDalvanceDurata TherapeuticsNorth AmericaPharmaceuticalRegulation

Back to top